<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32170537</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-9546</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Purinergic signalling</Title><ISOAbbreviation>Purinergic Signal</ISOAbbreviation></Journal><ArticleTitle>The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1<sup>G93A</sup> mice.</ArticleTitle><Pagination><StartPage>109</StartPage><EndPage>122</EndPage><MedlinePgn>109-122</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11302-020-09692-4</ELocationID><Abstract><AbstractText>The ATP-gated P2X7 ion channel has emerging roles in amyotrophic lateral sclerosis (ALS) progression. Pharmacological blockade of P2X7 with Brilliant Blue G can ameliorate disease in SOD1<sup>G93A</sup> mice, but recent data suggests that this antagonist displays poor penetration of the central nervous system (CNS). Therefore, the current study aimed to determine whether the CNS-penetrant P2X7 antagonist, JNJ-47965567, could ameliorate ALS progression in SOD1<sup>G93A</sup> mice. A flow cytometric assay revealed that JNJ-47965567 impaired ATP-induced cation dye uptake in a concentration-dependent manner in murine J774 macrophages. Female and male SOD1<sup>G93A</sup> mice were injected intraperitoneally with JNJ-47965567 (30&#xa0;mg/kg) or 2-(hydroxypropyl)-beta-cyclodextrin (vehicle control) three times a week from disease onset until end stage, when tissues were collected and studied. JNJ-47965567 did not impact weight loss, clinical score, motor (rotarod) coordination or survival compared to control mice. NanoString analysis revealed altered spinal cord gene expression in JNJ-47965567 mice compared to control mice, but such differences were not confirmed by quantitative PCR. Flow cytometric analyses revealed no differences between treatments in the frequencies or activation status of T cell or dendritic cell subsets in lymphoid tissues or in the concentrations of serum cytokines. Notably, serum IL-27, IFN&#x3b2; and IL-10 were present in relatively high concentrations compared to other cytokines in both groups. In conclusion, JNJ-47965567 administered thrice weekly from disease onset did not alter disease progression or molecular and cellular parameters in SOD1<sup>G93A</sup> mice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ly</LastName><ForeName>Diane</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-8454-1810</Identifier><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, 2522, Australia. dly@uow.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, 2522, Australia. dly@uow.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dongol</LastName><ForeName>Anjila</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3355-6585</Identifier><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuthbertson</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2903-2586</Identifier><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guy</LastName><ForeName>Thomas V</ForeName><Initials>TV</Initials><Identifier Source="ORCID">0000-0003-0926-7580</Identifier><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geraghty</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0001-9098-8224</Identifier><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sophocleous</LastName><ForeName>Reece A</ForeName><Initials>RA</Initials><Identifier Source="ORCID">0000-0002-8339-9090</Identifier><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sin</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-4096-128X</Identifier><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Bradley J</ForeName><Initials>BJ</Initials><Identifier Source="ORCID">0000-0001-6580-7655</Identifier><AffiliationInfo><Affiliation>Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>Debbie</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-6242-3944</Identifier><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yerbury</LastName><ForeName>Justin J</ForeName><Initials>JJ</Initials><Identifier Source="ORCID">0000-0003-2528-7039</Identifier><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, 2522, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sluyter</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-4909-686X</Identifier><AffiliationInfo><Affiliation>Illawarra Health and Medical Research Institute, Wollongong, NSW, 2522, Australia. rsluyter@uow.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Horizons and School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, 2522, Australia. rsluyter@uow.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Purinergic Signal</MedlineTA><NlmUniqueID>101250499</NlmUniqueID><ISSNLinking>1573-9538</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000590736">JNJ-47965567</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058920">Purinergic P2X Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>25X51I8RD4</RegistryNumber><NameOfSubstance UI="D009536">Niacinamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009536" MajorTopicYN="N">Niacinamide</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058920" MajorTopicYN="N">Purinergic P2X Receptor Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Motor neurone disease</Keyword><Keyword MajorTopicYN="N">Nqo1</Keyword><Keyword MajorTopicYN="N">P2X7 receptor</Keyword><Keyword MajorTopicYN="N">Purinergic receptor</Keyword><Keyword MajorTopicYN="N">SOD1G93A mice</Keyword></KeywordList><CoiStatement>The authors declare they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32170537</ArticleId><ArticleId IdType="pmc">PMC7166237</ArticleId><ArticleId IdType="doi">10.1007/s11302-020-09692-4</ArticleId><ArticleId IdType="pii">10.1007/s11302-020-09692-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol. 2016;138:225&#x2013;238. doi: 10.1016/b978-0-12-802973-2.00013-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/b978-0-12-802973-2.00013-6</ArticleId><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39:733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M, Pu HF, Chiu AY, Dal Canto M, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng H-X, Chen W, Zhai P, Sufit RL, Siddique T. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, Ke YD, Ittner LM, Halliday GM. ALS/FTLD: experimental models and reality. Acta Neuropathol. 2017;133:177&#x2013;196. doi: 10.1007/s00401-016-1666-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1666-6</ArticleId><ArticleId IdType="pubmed">28058507</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfohl SR, Halicek MT, Mitchell CS. Characterization of the contribution of genetic background and gender to disease progression in the SOD1 G93A mouse model of amyotrophic lateral sclerosis: a meta-analysis. J Neuromuscul Dis. 2015;2:137&#x2013;150. doi: 10.3233/jnd-140068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jnd-140068</ArticleId><ArticleId IdType="pmc">PMC4652798</ArticleId><ArticleId IdType="pubmed">26594635</ArticleId></ArticleIdList></Reference><Reference><Citation>McGoldrick P, Joyce PI, Fisher EM, Greensmith L. Rodent models of amyotrophic lateral sclerosis. Biochim Biophys Acta. 2013;1832:1421&#x2013;1436. doi: 10.1016/j.bbadis.2013.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2013.03.012</ArticleId><ArticleId IdType="pubmed">23524377</ArticleId></ArticleIdList></Reference><Reference><Citation>Sluyter R. The P2X7 receptor. Adv Exp Med Biol. 2017;1051:17&#x2013;53. doi: 10.1007/5584_2017_59.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/5584_2017_59</ArticleId><ArticleId IdType="pubmed">28676924</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S. The P2X7 receptor in infection and inflammation. Immunity. 2017;47:15&#x2013;31. doi: 10.1016/j.immuni.2017.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.06.020</ArticleId><ArticleId IdType="pubmed">28723547</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Mateos EM, Smith J, Nicke A, Engel T (2018) Regulation of P2X7 receptor expression and function in the brain. Brain Res Bull 151:153&#x2013;163. 10.1016/j.brainresbull.2018.12.008</Citation><ArticleIdList><ArticleId IdType="pubmed">30593878</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya A, Wang Q, Ao H, Shoblock JR, Lord B, Aluisio L, Fraser I, Nepomuceno D, Neff RA, Welty N, Lovenberg TW, Bonaventure P, Wickenden AD, Letavic MA (2013) Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol 170:624&#x2013;640. 10.1111/bph.12314</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3792000</ArticleId><ArticleId IdType="pubmed">23889535</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer W, Franke H, Krugel U, Muller H, Dinkel K, Lord B, Letavic MA, Henshall DC, Engel T. Critical evaluation of P2X7 receptor antagonists in selected seizure models. PLoS One. 2016;11:e0156468. doi: 10.1371/journal.pone.0156468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0156468</ArticleId><ArticleId IdType="pmc">PMC4900628</ArticleId><ArticleId IdType="pubmed">27281030</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Pacheco A, Diaz-Hernandez M, Arribas-Blazquez M, Sanz-Rodriguez A, Olivos-Ore LA, Artalejo AR, Alves M, Letavic M, Miras-Portugal MT, Conroy RM, Delanty N, Farrell MA, O'Brien DF, Bhattacharya A, Engel T, Henshall DC. Transient P2X7 receptor antagonism produces lasting reductions in spontaneous seizures and gliosis in experimental temporal lobe epilepsy. J Neurosci. 2016;36:5920&#x2013;5932. doi: 10.1523/jneurosci.4009-15.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.4009-15.2016</ArticleId><ArticleId IdType="pmc">PMC6601816</ArticleId><ArticleId IdType="pubmed">27251615</ArticleId></ArticleIdList></Reference><Reference><Citation>Karasawa A, Kawate T (2016) Structural basis for subtype-specific inhibition of the P2X7 receptor. Elife 5. 10.7554/eLife.22153</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5176352</ArticleId><ArticleId IdType="pubmed">27935479</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, Banati RR, Anand P. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006;6:12. doi: 10.1186/1471-2377-6-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-6-12</ArticleId><ArticleId IdType="pmc">PMC1413551</ArticleId><ArticleId IdType="pubmed">16512913</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanovas A, Hernandez S, Tarabal O, Rossello J, Esquerda JE. Strong P2X4 purinergic receptor-like immunoreactivity is selectively associated with degenerating neurons in transgenic rodent models of amyotrophic lateral sclerosis. J Comp Neurol. 2008;506:75&#x2013;92. doi: 10.1002/cne.21527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.21527</ArticleId><ArticleId IdType="pubmed">17990272</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Ambrosi N, Finocchi P, Apolloni S, Cozzolino M, Ferri A, Padovano V, Pietrini G, Carri MT, Volonte C. The proinflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis. J Immunol. 2009;183:4648&#x2013;4656. doi: 10.4049/jimmunol.0901212.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0901212</ArticleId><ArticleId IdType="pubmed">19734218</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandelman M, Peluffo H, Beckman JS, Cassina P, Barbeito L. Extracellular ATP and the P2X7 receptor in astrocyte-mediated motor neuron death: implications for amyotrophic lateral sclerosis. J Neuroinflammation. 2010;7:33. doi: 10.1186/1742-2094-7-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-33</ArticleId><ArticleId IdType="pmc">PMC2901222</ArticleId><ArticleId IdType="pubmed">20534165</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandelman M, Levy M, Cassina P, Barbeito L, Beckman JS. P2X7 receptor-induced death of motor neurons by a peroxynitrite/FAS-dependent pathway. J Neurochem. 2013;126:382&#x2013;388. doi: 10.1111/jnc.12286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12286</ArticleId><ArticleId IdType="pmc">PMC3716845</ArticleId><ArticleId IdType="pubmed">23646980</ArticleId></ArticleIdList></Reference><Reference><Citation>Cieslak M, Roszek K, Wujak M. Purinergic implication in amyotrophic lateral sclerosis-from pathological mechanisms to therapeutic perspectives. Purinergic Signal. 2019;15:1&#x2013;15. doi: 10.1007/s11302-018-9633-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11302-018-9633-4</ArticleId><ArticleId IdType="pmc">PMC6439052</ArticleId><ArticleId IdType="pubmed">30430356</ArticleId></ArticleIdList></Reference><Reference><Citation>Volonte C, Apolloni S, Parisi C, Amadio S. Purinergic contribution to amyotrophic lateral sclerosis. Neuropharmacology. 2016;104:180&#x2013;193. doi: 10.1016/j.neuropharm.2015.10.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2015.10.026</ArticleId><ArticleId IdType="pubmed">26514402</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervetto C, Frattaroli D, Maura G, Marcoli M. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism. Toxicology. 2013;311:69&#x2013;77. doi: 10.1016/j.tox.2013.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tox.2013.04.004</ArticleId><ArticleId IdType="pubmed">23583883</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S, Amadio S, Parisi C, Matteucci A, Potenza RL, Armida M, Popoli P, D'Ambrosi N, Volonte C. Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of amyotrophic lateral sclerosis. Dis Model Mech. 2014;7:1101&#x2013;1109. doi: 10.1242/dmm.017038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.017038</ArticleId><ArticleId IdType="pmc">PMC4142730</ArticleId><ArticleId IdType="pubmed">25038061</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett R, Sluyter V, Watson D, Sluyter R, Yerbury JJ. P2X7 antagonism using brilliant blue G reduces body weight loss and prolongs survival in female SOD1G93A amyotrophic lateral sclerosis mice. PeerJ. 2017;5:e3064. doi: 10.7717/peerj.3064.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.3064</ArticleId><ArticleId IdType="pmc">PMC5335685</ArticleId><ArticleId IdType="pubmed">28265522</ArticleId></ArticleIdList></Reference><Reference><Citation>Sluyter R, Bartlett R, Ly D, Yerbury JJ. P2X7 receptor antagonism in amyotrophic lateral sclerosis. Neural Regen Res. 2017;12:749&#x2013;750. doi: 10.4103/1673-5374.206643.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.206643</ArticleId><ArticleId IdType="pmc">PMC5461610</ArticleId><ArticleId IdType="pubmed">28616029</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya A, Biber K. The microglial ATP-gated ion channel P2X7 as a CNS drug target. Glia. 2016;64:1772&#x2013;1787. doi: 10.1002/glia.23001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23001</ArticleId><ArticleId IdType="pubmed">27219534</ArticleId></ArticleIdList></Reference><Reference><Citation>Sluyter R, Vine KL. N-alkyl-substituted Isatins enhance P2X7 receptor-induced interleukin-1beta release from murine macrophages. Mediat Inflamm. 2016;2016:2097219. doi: 10.1155/2016/2097219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/2097219</ArticleId><ArticleId IdType="pmc">PMC4972911</ArticleId><ArticleId IdType="pubmed">27524862</ArticleId></ArticleIdList></Reference><Reference><Citation>McLeod VM, Lau CL, Chiam MDF, Rupasinghe TW, Roessner U, Djouma E, Boon WC, Turner BJ. Androgen receptor antagonism accelerates disease onset in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Br J Pharmacol. 2019;176:2111&#x2013;2130. doi: 10.1111/bph.14657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14657</ArticleId><ArticleId IdType="pmc">PMC6555856</ArticleId><ArticleId IdType="pubmed">30849180</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, Bostrom A, Theodoss J, Al-Nakhala BM, Vieira FG, Ramasubbu J, Heywood JA. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler. 2008;9:4&#x2013;15. doi: 10.1080/17482960701856300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701856300</ArticleId><ArticleId IdType="pubmed">18273714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler JP, Mead R, Niessen HG, Petri S, Pradat PF, Robberecht W, Ruegg M, Schwalenstocker B, Stiller D, van den Berg L, Vieira F, von Horsten S. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler. 2010;11:38&#x2013;45. doi: 10.3109/17482960903545334.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903545334</ArticleId><ArticleId IdType="pubmed">20184514</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzipetros T, Kidd JD, Moreno AJ, Thompson K, Gill A, Vieira FG (2015) A quick phenotypic neurological scoring system for evaluating disease progression in the SOD1-G93A mouse model of ALS. J Vis Exp. 10.3791/53257</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692639</ArticleId><ArticleId IdType="pubmed">26485052</ArticleId></ArticleIdList></Reference><Reference><Citation>Geraghty NJ, Mansfield KJ, Fuller SJ, Watson D, Sluyter R. The P2X7 receptor is not essential for development of imiquimod-induced psoriasis-like inflammation in mice. Purinergic Signal. 2017;13:405&#x2013;415. doi: 10.1007/s11302-017-9569-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11302-017-9569-0</ArticleId><ArticleId IdType="pmc">PMC5714832</ArticleId><ArticleId IdType="pubmed">28597172</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, Fanek Z, Liu L, Chen Z, Rothstein JD, Ransohoff RM, Gygi SP, Antel JP, Weiner HL. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci. 2014;17:131&#x2013;143. doi: 10.1038/nn.3599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3599</ArticleId><ArticleId IdType="pmc">PMC4066672</ArticleId><ArticleId IdType="pubmed">24316888</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon H, Walters G, Paulsen AR, Scarisbrick IA. Astrocyte heterogeneity across the brain and spinal cord occurs developmentally, in adulthood and in response to demyelination. PLoS One. 2017;12:e0180697. doi: 10.1371/journal.pone.0180697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0180697</ArticleId><ArticleId IdType="pmc">PMC5507262</ArticleId><ArticleId IdType="pubmed">28700615</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson MP, Staff NP. Bornschlegl S, Butler GW, Maas ML, Kazamel M, Zubair A, Gastineau DA, Windebank AJ, Dietz AB. Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. PLoS One. 2017;12:e0182002. doi: 10.1371/journal.pone.0182002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0182002</ArticleId><ArticleId IdType="pmc">PMC5526569</ArticleId><ArticleId IdType="pubmed">28742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol. 2017;74:1446&#x2013;1454. doi: 10.1001/jamaneurol.2017.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.2255</ArticleId><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, Zhao W, Moore DH, Powell SZ, Appel SH. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;5:64&#x2013;79. doi: 10.1002/emmm.201201544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201201544</ArticleId><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean RK, McKay FC, Cretney E, Bye CR, Perera ND, Tomas D, Weston RA, Scheller KJ, Djouma E, Menon P, Schibeci SD, Marmash N, Yerbury JJ, Nutt SL, Booth DR, Stewart GJ, Kiernan MC, Vucic S, Turner BJ. Association of Regulatory T-cell expansion with progression of amyotrophic lateral sclerosis: a study of humans and a transgenic mouse model. JAMA Neurol. 2018;75:681&#x2013;689. doi: 10.1001/jamaneurol.2018.0035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0035</ArticleId><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Purvis HA, Anderson AE, Young DA, Isaacs JD, Hilkens CM. A negative feedback loop mediated by STAT3 limits human Th17 responses. J Immunol. 2014;193:1142&#x2013;1150. doi: 10.4049/jimmunol.1302467.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1302467</ArticleId><ArticleId IdType="pubmed">24973454</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. 2013;31:563&#x2013;604. doi: 10.1146/annurev-immunol-020711-074950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-020711-074950</ArticleId><ArticleId IdType="pmc">PMC3853342</ArticleId><ArticleId IdType="pubmed">23516985</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Cao C, Qin XY, Yu Y, Yuan J, Zhao Y, Cheng Y. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study. Sci Rep. 2017;7:9094. doi: 10.1038/s41598-017-09097-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09097-1</ArticleId><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeyachandran A, Mertens B, McKissick EA, Mitchell CS. Type I Vs. type II cytokine levels as a function of SOD1 G93A mouse amyotrophic lateral sclerosis disease progression. Front Cell Neurosci. 2015;9:462. doi: 10.3389/fncel.2015.00462.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00462</ArticleId><ArticleId IdType="pmc">PMC4664727</ArticleId><ArticleId IdType="pubmed">26648846</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbrizio P, Amadio S, Apolloni S, Volonte C. P2X7 receptor activation modulates autophagy in SOD1-G93A mouse microglia. Front Cell Neurosci. 2017;11:249. doi: 10.3389/fncel.2017.00249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2017.00249</ArticleId><ArticleId IdType="pmc">PMC5566572</ArticleId><ArticleId IdType="pubmed">28871219</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyffert C, Schmalzing G, Markwardt F. Dissecting individual current components of co-expressed human P2X1 and P2X7 receptors. Curr Top Med Chem. 2004;4:1719&#x2013;1730. doi: 10.2174/1568026043387160.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026043387160</ArticleId><ArticleId IdType="pubmed">15579104</ArticleId></ArticleIdList></Reference><Reference><Citation>Bo X, Jiang LH, Wilson HL, Kim M, Burnstock G, Surprenant A, North RA. Pharmacological and biophysical properties of the human P2X5 receptor. Mol Pharmacol. 2003;63:1407&#x2013;1416. doi: 10.1124/mol.63.6.1407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.63.6.1407</ArticleId><ArticleId IdType="pubmed">12761352</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo S, Bean BP. Inhibition of neuronal voltage-gated sodium channels by brilliant blue G. Mol Pharmacol. 2011;80:247&#x2013;257. doi: 10.1124/mol.110.070276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.110.070276</ArticleId><ArticleId IdType="pmc">PMC3141889</ArticleId><ArticleId IdType="pubmed">21536754</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu F, Dahl G. A permeant regulating its permeation pore: inhibition of pannexin 1 channels by ATP. Am J Phys Cell Physiol. 2009;296:C250&#x2013;C255. doi: 10.1152/ajpcell.00433.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00433.2008</ArticleId><ArticleId IdType="pmc">PMC2643853</ArticleId><ArticleId IdType="pubmed">18945939</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamaru Y, Takenouchi T, Murayama Y, Okada H, Imamura M, Shimizu Y, Hashimoto M, Mohri S, Yokoyama T, Kitani H. Anti-prion activity of brilliant blue G. PLoS One. 2012;7:e37896. doi: 10.1371/journal.pone.0037896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0037896</ArticleId><ArticleId IdType="pmc">PMC3365075</ArticleId><ArticleId IdType="pubmed">22693582</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad LI, Yerbury JJ, Turner BJ, Guest WC, Pokrishevsky E, O'Neill MA, Yanai A, Silverman JM, Zeineddine R, Corcoran L, Kumita JR, Luheshi LM, Yousefi M, Coleman BM, Hill AF, Plotkin SS, Mackenzie IR, Cashman NR. Intercellular propagated misfolding of wild-type cu/Zn superoxide dismutase occurs via exosome-dependent and -independent mechanisms. Proc Natl Acad Sci U S A. 2014;111:3620&#x2013;3625. doi: 10.1073/pnas.1312245111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1312245111</ArticleId><ArticleId IdType="pmc">PMC3948312</ArticleId><ArticleId IdType="pubmed">24550511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovanyi B, Csolle C, Calovi S, Hanuska A, Kato E, Koles L, Bhattacharya A, Haller J, Sperlagh B. The role of P2X7 receptors in a rodent PCP-induced schizophrenia model. Sci Rep. 2016;6:36680. doi: 10.1038/srep36680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep36680</ArticleId><ArticleId IdType="pmc">PMC5099752</ArticleId><ArticleId IdType="pubmed">27824163</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Alvarez N, Jimenez-Mateos EM, Engel T, Quinlan S, Reschke CR, Conroy RM, Bhattacharya A, Boylan GB, Henshall DC. Effects of P2X7 receptor antagonists on hypoxia-induced neonatal seizures in mice. Neuropharmacology. 2017;116:351&#x2013;363. doi: 10.1016/j.neuropharm.2017.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2017.01.005</ArticleId><ArticleId IdType="pubmed">28082183</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvath G, Otrokocsi L, Beko K, Baranyi M, Kittel A, Fritz-Ruenes PA, Sperlagh B. P2X7 receptors drive poly(I:C) induced autism-like behavior in mice. J Neurosci. 2019;39:2542&#x2013;2561. doi: 10.1523/JNEUROSCI.1895-18.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1895-18.2019</ArticleId><ArticleId IdType="pmc">PMC6435822</ArticleId><ArticleId IdType="pubmed">30683682</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly-Roberts DL, Namovic MT, Surber B, Vaidyanathan SX, Perez-Medrano A, Wang Y, Carroll WA, Jarvis MF. [3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors. Neuropharmacology. 2009;56:223&#x2013;229. doi: 10.1016/j.neuropharm.2008.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2008.06.012</ArticleId><ArticleId IdType="pubmed">18602931</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S, Amadio S, Montilli C, Volonte C, D'Ambrosi N. Ablation of P2X7 receptor exacerbates gliosis and motoneuron death in the SOD1-G93A mouse model of amyotrophic lateral sclerosis. Hum Mol Genet. 2013;22:4102&#x2013;4116. doi: 10.1093/hmg/ddt259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt259</ArticleId><ArticleId IdType="pubmed">23736299</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu BJ, Wiley JS. P2X7 as a scavenger receptor for innate phagocytosis in the brain. Br J Pharmacol. 2018;175:4195&#x2013;4208. doi: 10.1111/bph.14470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14470</ArticleId><ArticleId IdType="pmc">PMC6193880</ArticleId><ArticleId IdType="pubmed">30098011</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu BJ, Saunders BM, Jursik C, Wiley JS. The P2X7-nonmuscle myosin membrane complex regulates phagocytosis of nonopsonized particles and bacteria by a pathway attenuated by extracellular ATP. Blood. 2010;115:1621&#x2013;1631. doi: 10.1182/blood-2009-11-251744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-11-251744</ArticleId><ArticleId IdType="pubmed">20007545</ArticleId></ArticleIdList></Reference><Reference><Citation>Ou A, Gu BJ, Wiley JS. The scavenger activity of the human P2X7 receptor differs from P2X7 pore function by insensitivity to antagonists, genetic variation and sodium concentration: relevance to inflammatory brain diseases. Biochim Biophys Acta Mol basis Dis. 2018;1864:1051&#x2013;1059. doi: 10.1016/j.bbadis.2018.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2018.01.012</ArticleId><ArticleId IdType="pubmed">29329985</ArticleId></ArticleIdList></Reference><Reference><Citation>Bin Dayel A, Evans RJ, Schmid R. Mapping the site of action of human P2X7 receptor antagonists AZ11645373, brilliant blue G, KN-62, Calmidazolium, and ZINC58368839 to the Intersubunit allosteric pocket. Mol Pharmacol. 2019;96:355&#x2013;363. doi: 10.1124/mol.119.116715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.119.116715</ArticleId><ArticleId IdType="pmc">PMC6701605</ArticleId><ArticleId IdType="pubmed">31263019</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecsernyes M, Fenyvesi F, Bacskay I, Deli MA, Szente L, Fenyvesi E. Cyclodextrins, blood-brain barrier, and treatment of neurological diseases. Arch Med Res. 2014;45:711&#x2013;729. doi: 10.1016/j.arcmed.2014.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2014.11.020</ArticleId><ArticleId IdType="pubmed">25482528</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J, Ho D, Calingasan NY, Pipalia NH, Lin MT, Beal MF. Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease. J Exp Med. 2012;209:2501&#x2013;2513. doi: 10.1084/jem.20121239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20121239</ArticleId><ArticleId IdType="pmc">PMC3526350</ArticleId><ArticleId IdType="pubmed">23209315</ArticleId></ArticleIdList></Reference><Reference><Citation>Maulik M, Ghoshal B, Kim J, Wang Y, Yang J, Westaway D, Kar S. Mutant human APP exacerbates pathology in a mouse model of NPC and its reversal by a beta-cyclodextrin. Hum Mol Genet. 2012;21:4857&#x2013;4875. doi: 10.1093/hmg/dds322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds322</ArticleId><ArticleId IdType="pubmed">22869680</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazzerro E, Baldassari S, Assereto S, Fruscione F, Pistorio A, Panicucci C, Volpi S, Perruzza L, Fiorillo C, Minetti C, Traggiai E, Grassi F, Bruno C. Enhancement of muscle T regulatory cells and improvement of muscular dystrophic process in mdx mice by blockade of extracellular ATP/P2X Axis. Am J Pathol. 2015;185:3349&#x2013;3360. doi: 10.1016/j.ajpath.2015.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2015.08.010</ArticleId><ArticleId IdType="pubmed">26465071</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo TY, Lee JG, Yan JJ, Jang JY, Ju KD, Han M, Oh KH, Ahn C, Yang J. The P2X7 receptor antagonist, oxidized adenosine triphosphate, ameliorates renal ischemia-reperfusion injury by expansion of regulatory T cells. Kidney Int. 2017;92:415&#x2013;431. doi: 10.1016/j.kint.2017.01.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.01.031</ArticleId><ArticleId IdType="pubmed">28396117</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Martinez L, de la Torre M, Toivonen JM, Zaragoza P, Garcia-Redondo A, Calvo AC, Osta R. Circulating cytokines could not be good prognostic biomarkers in a mouse model of amyotrophic lateral sclerosis. Front Immunol. 2019;10:801. doi: 10.3389/fimmu.2019.00801.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00801</ArticleId><ArticleId IdType="pmc">PMC6473074</ArticleId><ArticleId IdType="pubmed">31031774</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>